Could Esperion Therapeutics Inc See a Reversal After Today’s Strong Options Activity?

 Could Esperion Therapeutics Inc See a Reversal After Today's Strong Options Activity?

In today’s session Esperion Therapeutics Inc (ESPR) recorded an unusually high (867) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious ESPR decrease. With 867 contracts traded and 9674 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: ESPR161021P00012000 closed last at: $0.45 or 50% down. About 250,607 shares traded hands. Esperion Therapeutics Inc (NASDAQ:ESPR) has declined 29.61% since March 14, 2016 and is downtrending. It has underperformed by 35.23% the S&P500.

Analysts await Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings on November, 3. They expect $-0.88 earnings per share, down 54.39% or $0.31 from last year’s $-0.57 per share. After $-0.62 actual earnings per share reported by Esperion Therapeutics Inc for the previous quarter, Wall Street now forecasts 41.94% negative EPS growth.

Esperion Therapeutics Inc (NASDAQ:ESPR) Ratings Coverage

Out of 13 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 7 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 54% are positive. Esperion Therapeutics has been the topic of 30 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Barclays Capital downgraded Esperion Therapeutics Inc (NASDAQ:ESPR) rating on Wednesday, June 29. Barclays Capital has “Equal-Weight” rating and $13 price target. On Wednesday, February 24 the stock rating was maintained by Barclays Capital with “Overweight”. Lake Street maintained it with “Buy” rating and $27 target price in Wednesday, June 29 report. RBC Capital Markets maintained Esperion Therapeutics Inc (NASDAQ:ESPR) rating on Friday, November 6. RBC Capital Markets has “Outperform” rating and $65 price target. As per Wednesday, June 29, the company rating was downgraded by Credit Suisse. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) has “Sell” rating given on Tuesday, September 29 by Chardan Capital Markets. Needham upgraded Esperion Therapeutics Inc (NASDAQ:ESPR) on Wednesday, August 19 to “Strong Buy” rating. Chardan Capital Markets maintained Esperion Therapeutics Inc (NASDAQ:ESPR) rating on Friday, August 7. Chardan Capital Markets has “Sell” rating and $40.0 price target. As per Monday, October 26, the company rating was initiated by Lake Street. Stifel Nicolaus maintained it with “Buy” rating and $64 target price in Thursday, February 25 report.

According to Zacks Investment Research, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.”

Insitutional Activity: The institutional sentiment increased to 1.27 in 2016 Q2. Its up 0.11, from 1.16 in 2016Q1. The ratio is positive, as 13 funds sold all Esperion Therapeutics Inc shares owned while 24 reduced positions. 9 funds bought stakes while 38 increased positions. They now own 14.43 million shares or 7.41% less from 15.58 million shares in 2016Q1.
Legal General Grp Inc Inc Public Ltd Com reported 2,187 shares or 0% of all its holdings. Invesco, a Georgia-based fund reported 176,229 shares. Tekla Cap Ltd Liability Corp holds 0.04% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 102,800 shares. Gam Hldg Ag has 128,000 shares for 0.02% of their US portfolio. Blackrock Fund Advisors holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 657,919 shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 506 shares. Geode Capital Mngmt Ltd Liability accumulated 109,473 shares or 0% of the stock. Moreover, Tru Of Vermont has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR) for 300 shares. Morgan Stanley has 126,530 shares for 0% of their US portfolio. The Pennsylvania-based Cim Mangement has invested 0.07% in Esperion Therapeutics Inc (NASDAQ:ESPR). Barclays Public Ltd Com holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 388 shares. Bnp Paribas Arbitrage Sa last reported 565 shares in the company. Discovery Capital Ltd Liability Corporation Ct reported 1.05 million shares or 0.24% of all its holdings. Bb Biotech Ag reported 1.01M shares or 0.39% of all its holdings. Teachers Advsr holds 0% of its portfolio in Esperion Therapeutics Inc (NASDAQ:ESPR) for 21,380 shares.

Esperion Therapeutics, Inc. is a pharmaceutical company. The company has a market cap of $254.81 million. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with elevated LDL-C. It currently has negative earnings. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

ESPR Company Profile

Esperion Therapeutics, Inc., incorporated on January 22, 2008, is a pharmaceutical company. The Firm is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Firm is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.

More news for Esperion Therapeutics Inc (NASDAQ:ESPR) were recently published by: Fool.com, which released: “Esperion Therapeutics Inc Sinks After FDA Says, “Ask Us in 2019″” on June 29, 2016. Prnewswire.com‘s article titled: “Shareholder Class Action Filed Against Esperion Therapeutics, Inc. – ESPR” and published on January 14, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment